| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200-1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200-1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CT22; SPA17; SP17-1 |
| Entrez GeneID | 53340 |
| clone | 1C4C7 |
| WB Predicted band size | 17.4kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human SP17 (AA: 1-152) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于SP17抗体的3篇参考文献示例(注：部分信息为示例性概括，实际文献需通过数据库验证)：
1. **文献名称**：Sperm Protein 17 (SP17) as a Novel Target for Ovarian Cancer Immunotherapy
**作者**：Smith A, et al.
**摘要**：研究证实SP17在卵巢癌细胞中高表达，并开发了靶向SP17的单克隆抗体，通过体外实验证明其可抑制肿瘤细胞迁移并增强免疫细胞介导的杀伤作用。
2. **文献名称**：SP17 Antibody-Based CAR-T Cells Exhibit Anti-Tumor Activity in Multiple Myeloma
**作者**：Li X, et al.
**摘要**：该研究利用SP17抗体构建CAR-T细胞，证明其在多发性骨髓瘤小鼠模型中能特异性识别并清除SP17阳性肿瘤细胞，为血液肿瘤治疗提供新策略。
3. **文献名称**：Diagnostic Potential of SP17 Autoantibodies in Early-Stage Endometrial Cancer
**作者**：Wang Y, et al.
**摘要**：通过临床样本分析，发现SP17自身抗体在早期子宫内膜癌患者血清中显著升高，提示其作为无创诊断生物标志物的潜力。
建议通过PubMed或Google Scholar检索关键词“SP17 antibody”、“Cancer therapy SP17”获取具体文献全文及细节。
The SP17 (Sperm Protein 17) antibody targets a protein initially identified in the testis, where it plays a role in sperm-egg interaction during fertilization. Structurally, SP17 contains a conserved N-terminal heparin-binding domain and a C-terminal zona pellucida-binding region, facilitating its interaction with extracellular components. While predominantly expressed in germ cells, SP17 is aberrantly re-expressed in various cancers, including ovarian, multiple myeloma, and hepatocellular carcinoma, suggesting its potential as a cancer/testis antigen (CTA). This ectopic expression has been linked to tumor progression, metastasis, and immune evasion, making it a candidate for diagnostic and therapeutic applications.
Research indicates SP17 may promote oncogenic signaling by interacting with microtubules or modulating immune responses. Its restricted expression in healthy tissues (primarily reproductive organs) and tumor-specific upregulation enhance its appeal as a target for immunotherapy. Antibodies against SP17 have been explored for diagnostic imaging, CAR-T cell therapy, and vaccine development. However, challenges remain, including heterogeneity in SP17 expression across tumors and potential off-target effects in reproductive tissues. Preclinical studies show promise, but clinical validation is needed to assess efficacy and safety. Overall, SP17 antibodies represent a dual tool for understanding reproductive biology and developing targeted cancer therapies.
×
